MEAI

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Retrieved on: 
Wednesday, January 25, 2023
Psychoactive drug, Annual general meeting, Obesity, Hebrew University of Jerusalem, FSE, Hebrew language, Metabolic syndrome, CWY, Drug development, Therapy, MEAI, Eleazar Sukenik, CSE, Associate, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023.

Key Points: 
  • The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearmind’s drug candidate MEAI for treating obesity and metabolic syndrome.
  • Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the world’s largest annual analytical chemistry conferences.
  • Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearmind’s robust collaboration with the Hebrew University and its technology transfer company Yissum .

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Retrieved on: 
Tuesday, January 17, 2023
Bar-Ilan University, CWY, CSE, FSE, SUD, Addiction, Gonda, Sucrose, MEAI, Survival, Therapy, Observation, Cocaine, RATS, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to cocaine addiction.

Key Points: 
  • The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to cocaine addiction.
  • The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel.
  • As previously announced (see press release August 24, 2022), Clearmind's proprietary MEAI at a dose of 5mg/kg, demonstrated unique ability to decrease cocaine craving and potentially become the first dedicated cocaine addiction treatment.
  • The empirical data show that MEAI is a potential treatment for cocaine addiction, in particular, and SUD, in general.

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Retrieved on: 
Tuesday, January 17, 2023
Bar-Ilan University, CWY, Patent, CSE, United States Patent and Trademark Office, FSE, Addiction, Gonda, Sucrose, Palmitoylethanolamide, MEAI, Central nervous system, Survival, Cocaine, Crave, RATS, TEL, Pharmaceutical industry

TEL AVIV, Israel, Jan. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY).

Key Points: 
  • The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process.
  • The results are in connection with the ongoing collaboration between the Company and Clearmind and the provisional patent application for treating cocaine addiction with Clearmind, based on SciSparc’s CannAmide™’s active ingredient Palmitoylethanolamide and Clearmind’s MEAI.
  • The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel.
  • As previously announced on August 24, 2022, Clearmind's proprietary MEAI at a dose of 5mg/kg, may be effective in the treatment of cocaine addiction by decreased craving for cocaine.

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Retrieved on: 
Tuesday, January 10, 2023
CWY, CSE, FSE, AUD, FDA, MEAI, Therapy, Clinical trial, Good, GMP, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.
  • “Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.
  • “Our pre-clinical positive results indicated the potential of our unique treatment for AUD.
  • We continue to execute the final steps necessary in order to commence our clinical program.”
    The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023
TEL, Central nervous system, MEAI, Human, Microdeletion syndrome, Overweight, Triglyceride, FSE, Animal, Palmitoylethanolamide, CSE, World Health Organization, CWY, Weight loss, Hebrew University of Jerusalem, Obesity, Eleazar Sukenik, Motivation, Liver, Pharmaceutical industry, Dietary supplement

TEL AVIV, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced initial positive pre-clinical results for treatment for obesity and the potential treatment of metabolic syndromes using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY).

Key Points: 
  • "We believe that this virtually untapped multibillion-dollar market creates significant opportunities for our joined collaboration with Clearmind by developing a unique drug candidate for the market to treat obesity."
  • Thus, this treatment may be beneficial for the treatment of compulsive-reward-seeking behavior or excessive consumption of sweet foods.
  • Mr. Oz Adler, the Chief Executive Officer and Chief Financial Officer of the Company, is a director of Clearmind.
  • Mr. Amitai Weiss is the Chairman of the board of directors of both Clearmind and the Company.

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023
Death, Liver disease, Associate, MEAI, Morgan Stanley, Metabolism, Human, Research, Hebrew language, Triglyceride, Overweight, FSE, LSD, Risk, Stanley, Animal, Drug development, CSE, Fatty liver disease, World Health Organization, Psilocybin, Novo Nordisk, CWY, Weight loss, Metabolic syndrome, Therapy, Hebrew University of Jerusalem, Obesity, Eleazar Sukenik, Motivation, Lilly, Liver, Dietary supplement, Pharmaceutical industry, Yissum Research Development Company of the Hebrew University, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.

Key Points: 
  • It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
  • Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
  • This underserved multibillion-dollar market creates significant opportunities for Clearmind to generate substantial revenues, should MEAI reach the market as an obesity treatment.

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Retrieved on: 
Wednesday, December 28, 2022
Azerbaijan and Organization for Economic Co-operation, National Survey on Drug Use and Health, Clinical trial, Substance abuse, OECD, MEAI, AUD, Public health, Government budget balance, D-8 Organization for Economic Cooperation, Depression, FSE, Parity, Trial of the century, Person, Sheba Medical Center, Patient, CSE, Purchasing power parity, CWY, Personality, Therapy, Phase, Quality of life, Alcoholism, Woman, IMCA, Pharmaceutical industry, Health, Development

Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced the first agreement to conduct its first- in-human clinical trial using its MEAI-based CMND-100 compound aimed at treating alcohol use disorder ("AUD").

Key Points: 
  • The agreement was signed with the Phase I/II unit at the IMCA center in Ramat Gan, Israel.
  • "We are thrilled to have the first clinical center join our clinical trial and pleased that our innovative approach to treating AUD is well-received by the medical community.
  • It is our intention to sign a similar agreement with a clinical center in the United States.
  • The economic loss results from missing labor days, related diseases, and other derivatives of excessive alcohol use.

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Retrieved on: 
Wednesday, December 21, 2022
MEAI, MDXX, Patent, Beer, United States Patent and Trademark Office, FSE, News, Growth, CSE, Information services, Energy drink, CWY, Health, Therapy, Pharmacy, Food industry, Pharmaceutical industry, Fine chemical

Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute.

Key Points: 
  • Similar patents have already been granted to Clearmind for the MEAI-based alcohol substitute in Europe and India.
  • 11,077,072 B2 – is a major milestone, given the increasing popularity and growth in sales of non-alcoholic wine, beer and spirits.
  • It strengthens our prospects for a new large market, different from the pharma market and with short-term potential for considerable revenue generation.” Zuloff-Shani added.
  • The patent follows the appointment of former Red Bull Canada executive Nicholas Kadysh as special advisor on the regulatory development of MEAI as an alcohol substitute.

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Retrieved on: 
Thursday, December 15, 2022
PEA, Acquisition, Canadian Securities Exchange, MEAI, Depression, Gonda, Clinical trial, Pharmacology, Research, Outline, Mental health, FDA, Hebrew University of Jerusalem, Cocaine, AUD, Science, FSE, Bar-Ilan University, Central nervous system, University, Frankfurt Stock Exchange, CWY, IPO, CSE, Eleazar Sukenik, IP, Obesity, Patent, Development, Patient, Therapy, Pharmaceutical industry, Management, BIRAD

Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.
  • We believe our proprietary CMND-100, 5-methoxy-2-aminoindane (“MEAI”)- based treatment can help provide relief to millions around the world.
  • I joined Clearmind when the company was founded, after a thorough examination of the science and the psychedelic fields.
  • CEO of Clearmind Medicine Inc.
    Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Retrieved on: 
Tuesday, December 13, 2022
Acquisition, MEAI, Clinical trial, Animal, Ministry, Pharmacology, Food, FDA, AUD, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, FSE, Human, CWY, CSE, Drug discovery, Toxicology, Research, IND, Patent, Therapy, Pharmaceutical industry, Fine chemical, Health

Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, today announced it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at  treating alcohol use disorder (AUD), in preparation for its first in-human clinical trial.

Key Points: 
  • As part of this year-long process, the company preformed pharmacology, pharmacokinetics, and toxicology assessments on the MEAI-based compound.
  • Previous pre-clinical studies using MEAI demonstrated a high safety profile and indications of a significant dose-dependent effect reducing alcohol consumption in treated animals.
  • Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
  • The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.